All six claims lack verifiable support in peer-reviewed literature or registered clinical trials. Two citations (New England Journal of Medicine 2023; University of Copenhagen 2024 study) could not be validated. While retatrutide is a real GLP-1/GIP/glucagon receptor agonist under clinical development, the specific mechanistic and physiological claims about heart rate effects, pacemaker cell biology, and pathway targeting lack published evidence in standard databases. Without access to cited studies or underlying data, these claims cannot be assessed as scientifically supported.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
can reta affect heart rate?
Video transcriptshow
Can RETA affect heart rate? Well, the research says 100% it can. So save this video because no one else in the pep space will actually break this down in a way that you can understand like I will. In a study on RETA published in the New England Journal of Medicine in 2023, they measured heart rate over the span of 48 weeks. What they found was that the compound seemed to raise resting heart rate b…
Show full video transcript
y about up to 10 beats per minute. This is at the highest 12 milligram dose and it peaked around 24 weeks in. This is because of what I like to call the dual throttle effect and it can be broken down into two parts. First is GLP-1 sensitivity of pacemaker cells. Now when you hear pacemaker, you probably think of the mechanical one invented by man. But the body actually has its own built-in pacemaker you probably think of the mechanical one invented by man but the body actually has its own built-in pacemaker cells every heartbeat starts as an electrical signal from those cells they're literally what sets the pace but in 2024 a team at the university of copenhagen found glp-1 receptors sitting on those same cells so when gl GLP-1 hits them, they fire faster directly, not through the nervous system. RETA is designed to work on those same GLP-1 activating system. But the second part is just as big of a factor, and it's what separates RETA from all the other GLP-1s out there. But real quick, you probably won't ever see my face again, so hit the follow button for more science-backed breakdowns like this. This second part is the glucagon pathway activation. Glucagon is a signal used by the body to increase sugar into the bloodstream from the liver. Now, there's a lot of ongoing research in this part, but what it shows is that glucagon appears to have its own pathway that can increase heart rate, and RETA is designed to work on that same glucagon pathway. So there's no question that it can raise heart rate, but so can caffeine, adrenaline, stress, and exercise. These things aren't bad. They just have specific purposes and use cases. So keep that in mind as you research.
Show lessClaim breakdown
6 claims“RETA can affect heart rate.”
No PubMed abstracts, clinical trial data, or published literature linking retatrutide (RETA) to heart rate effects were identified. The clinical trials found (NCT03462251, NCT01244750) do not address retatrutide or heart rate outcomes.
Supporting studies
“RETA, at the highest 12 milligram dose, raised resting heart rate by up to 10 beats per minute, peaking around 24 weeks.”
No New England Journal of Medicine 2023 article on retatrutide and heart rate was found in PubMed. No clinical trial data exists to support the specific quantitative claim of a 10 bpm increase peaking at 24 weeks.
Supporting studies
“GLP-1 sensitivity of pacemaker cells causes them to fire faster directly, not through the nervous system, when GLP-1 hits them.”
No published literature or clinical trials describing direct GLP-1 receptor activation on pacemaker cells (independent of nervous system) was found. The University of Copenhagen 2024 reference could not be verified in PubMed or ClinicalTrials.gov.
“RETA is designed to work on GLP-1 activating system.”
No published mechanism studies or clinical trials explicitly documenting retatrutide's design targeting GLP-1 activation pathways were found. Mechanistic design rationale is not available in accessible literature.
“Glucagon appears to have its own pathway that can increase heart rate.”
No PubMed abstracts or clinical trials specifically linking glucagon to independent heart rate elevation were identified. The trials found (NCT04856800, NCT01337440) do not address glucagon and heart rate mechanisms.
“RETA is designed to work on the glucagon pathway.”
No published literature or clinical trials documenting retatrutide's glucagon pathway design rationale were found. Design intent regarding glucagon mechanism is not verifiable in accessible scientific databases.
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error